Navigation Links
Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1
Date:12/6/2007

DENVER, Dec. 6 /PRNewswire/ -- Some 5,000 COPD patients will be tested to determine the prevalence of Alpha-1 Antitrypsin Deficiency (Alpha-1) in a study marking a major cooperative effort between the Alpha-1 Foundation and the American Association for Respiratory Care (AARC).

The principal investigator is Robert A. Sandhaus, MD, PhD, of the Division of Pulmonary Medicine, National Jewish Medical and Research Center in Denver. Sandhaus is also the Clinical Director of the Alpha-1 Foundation.

According to Sandhaus, "If the current literature is correct, the study should identify about 50 to 100 individuals who are unaware they have COPD due to Alpha-1. In addition, the study should identify about 300 people who are carrying a single abnormal Alpha-1 gene. All will be counseled about the potential risk to their children and family members."

Sandhaus points to an intriguing possibility. "If this study confirms what much smaller studies have suggested about Alphas hidden in the COPD population, there could be as many as 400,000 individuals in the US who have lung disease due to Alpha-1 and don't know it."

More than 12 million people have been diagnosed with COPD (Chronic Obstructive Pulmonary Disease), an umbrella term that includes emphysema and chronic bronchitis. COPD is the 4th leading cause of death in the United States, and is expected to be the third leading killer by 2020. Alpha-1, sometimes called "genetic COPD," is the most common known genetic risk factor for emphysema.

Sandhaus believes the study will demonstrate the effectiveness of using respiratory therapists to perform significant pulmonary clinical research.

"Respiratory therapists will have a critical role as more genetic factors (in lung, airway and sleep disorders) are identified," said Alpha-1 Foundation President and CEO John W. Walsh. "The expanding role of the RT in supporting the physician will accelerate early detection and access to appropriate care."

Thomas Kallstrom, AARC Chief Operating Officer, is the study coordinator for the AARC. "The involvement of respiratory therapists in this process is a natural relationship," Kallstrom said. "We're proud to be part of this monumental study."

The Alpha-1 Foundation and the AARC cooperated to propose, design and run the study, which will enroll 5,000 people at 15 academic sites around the United States. To be eligible, a patient must have been referred for pulmonary function testing at the site. Any patient meeting COPD criteria (as defined by GOLD, the Global Initiative for Chronic Obstructive Lung Disease) will be offered enrollment in the study.

The study requires only about 30 minutes of the subject's time, and participants will receive the results. If they are positive for Alpha-1, they will receive educational information about the condition and will be encouraged to call a toll-free number to speak with the Alpha-1 genetic counselor at the Medical University of South Carolina.

Epidemiology and AAT genotyping for the study will be done at the University of Florida Alpha-1 Genetics Laboratory run by Mark L. Brantly, MD. Data coordination and statistical analysis will be done by James Murphy, PhD, at National Jewish.

Jorge Zamudio, MD, is the Alpha-1 Foundation coordinator.

The study is supported in part by an unrestricted charitable contribution from Talecris Biotherapeutics.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Mark Brantly http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=54431 Charlie Strange http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=54427 Michael Campos http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=54425 Adam Wanner http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=54278 Robert Sandhaus http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=54274 John Walsh http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=54964 Edwin Silverman http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=69223 Byron Thomashow http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=69327


'/>"/>
SOURCE Alpha-1 Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... PUNE, India , May 27, 2016 ... in the instances of hypertension is driving ambulatory blood ... muscles lose their elasticity and their ability to respond ... blood pressure. This condition can lead to various cardiovascular ... and peripheral vascular disease. These diseases are growing in ...
(Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... 2016 , ... After a year and a half of planning the Multiple Pathways of ... Multiple Pathways of Recovery Conference was held May 2 -4, 2016 at the Mystic ... came together to explore the many pathways individuals use to get into and sustain their ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue ... Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields ... Director of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health ...
(Date:5/27/2016)... ... , ... This campaign aims to provide a path to improved education and ... and change. , As nearly 795,000 Americans suffering from a new or recurrent stoke ... with an estimated 129,000 of these people dying from stroke, it’s become our nation’s ...
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in ... courtesy of leaders in the nursing and health care industry. It also provides ... and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is adding ...
(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after the ... for an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center ... Market Committee (FOMC) dot charts are of interest to the press for their noise ...
Breaking Medicine News(10 mins):